HomeCompareCLSN vs MRK

CLSN vs MRK: Dividend Comparison 2026

CLSN yields 102.74% · MRK yields 2.76%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CLSN wins by $4.30M in total portfolio value
10 years
CLSN
CLSN
● Live price
102.74%
Share price
$1.95
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.36M
Annual income
$1,494,304.71
Full CLSN calculator →
MRK
Merck & Co. Inc.
● Live price
2.76%
Share price
$120.31
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$56.8K
Annual income
$9,798.13
Full MRK calculator →

Portfolio growth — CLSN vs MRK

📍 CLSN pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCLSNMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CLSN + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CLSN pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CLSN
Annual income on $10K today (after 15% tax)
$8,733.18/yr
After 10yr DRIP, annual income (after tax)
$1,270,159.00/yr
MRK
Annual income on $10K today (after 15% tax)
$234.56/yr
After 10yr DRIP, annual income (after tax)
$8,328.41/yr
At 15% tax rate, CLSN beats the other by $1,261,830.59/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CLSN + MRK for your $10,000?

CLSN: 50%MRK: 50%
100% MRK50/50100% CLSN
Portfolio after 10yr
$2.21M
Annual income
$752,051.42/yr
Blended yield
34.09%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

CLSN
Analyst Ratings
6
Buy
2
Hold
1
Sell
Consensus: Buy
Altman Z
-7819.1
Piotroski
3/9
MRK
Analyst Ratings
25
Buy
11
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+6.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CLSN buys
0
MRK buys
0
No recent congressional trades found for CLSN or MRK in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCLSNMRK
Forward yield102.74%2.76%
Annual dividend / share$2.00$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%32.7%
Portfolio after 10y$4.36M$56.8K
Annual income after 10y$1,494,304.71$9,798.13
Total dividends collected$3.90M$28.9K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyBuy

Year-by-year: CLSN vs MRK ($10,000, DRIP)

YearCLSN PortfolioCLSN Income/yrMRK PortfolioMRK Income/yrGap
1← crossover$20,974$10,274.32$11,206$366.19+$9.8KCLSN
2$42,582$20,139.91$12,650$502.35+$29.9KCLSN
3$83,777$38,213.45$14,407$694.19+$69.4KCLSN
4$159,904$70,262.72$16,585$967.82+$143.3KCLSN
5$296,433$125,336.27$19,342$1,363.89+$277.1KCLSN
6$534,334$217,150.75$22,913$1,947.19+$511.4KCLSN
7$937,555$365,816.85$27,662$2,823.89+$909.9KCLSN
8$1,603,062$599,878.65$34,159$4,173.35+$1.57MCLSN
9$2,673,868$958,591.11$43,337$6,308.80+$2.63MCLSN
10$4,355,343$1,494,304.71$56,776$9,798.13+$4.30MCLSN

CLSN vs MRK: Complete Analysis 2026

CLSNStock

Celsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.

Full CLSN Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this CLSN vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CLSN vs SCHDCLSN vs JEPICLSN vs OCLSN vs KOCLSN vs MAINCLSN vs JNJCLSN vs ABBVCLSN vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.